Genetic testing agency 23andMe stated on Monday it’s decreasing about 40 per cent, or 200 staff, from its workforce and discontinuing additional improvement of all its therapies as a part of a restructuring program.
“We’re taking these troublesome however obligatory actions as we restructure 23andMe and concentrate on the long-term success of our core client enterprise and analysis partnerships,” stated CEO Anne Wojcicki.
The corporate stated it’s evaluating strategic options, together with licensing agreements and asset gross sales, for its therapies in improvement.
Wojcicki, who has been attempting to take the corporate non-public since April, is going through a tricky problem after impartial administrators of 23andMe resigned in September, after not receiving a passable take-private provide from the CEO.
In July, the CEO and co-founder proposed to accumulate all excellent shares of the agency not already owned by her or her associates for 40 cents every.
After Monday’s restructuring plan, the corporate expects annualized value financial savings of greater than US$35 million.
